MMS22L

Across TCGA pan-cancer cohorts, MMS22L RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated MMS22L data layer compared with 7 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MMS22L RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MMS22L expression acts as an unfavorable survival marker, although some lineages such as KIRC and THYM show a favorable association.

KIRP, MESO, and LIHC are the cancer types where MMS22L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.780	0.925	<.001	114	view →
MESO	OS	Median	All	0.266	0.507	<.001	114	view →
LIHC	DFS	Median	All	0.453	0.627	<.001	106	view →
ACC	DFS	Median	All	0.380	0.777	<.001	89	view →
KICH	DFS	Median	II,III,IV	0.549	0.922	.002	55	view →
LGG	OS	Median	All	0.714	0.909	<.001	53	view →
KIRC	DFS	Median	III,IV	0.769	0.493	.001	34	view →
SARC	OS	Tertile	All	0.434	0.784	<.001	34	view →
UCEC	DFS	Median	All	0.797	0.877	.003	30	view →
THYM	OS	Tertile	All	1.000	0.735	.007	26	view →
READ	OS	Median	All	0.911	0.325	.006	25	view →
OV	OS	Median	IV	0.762	0.463	.002	20	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

MMS22L–KIRP (DFS)

Open the KIRP breakdown →